on July 24, 2003
Published online before print July 24, 2003, doi: 10.1161/01.STR.0000083624.74929.32
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 10, 2003
From the Max Planck Institute for Neurological Research (C.D., B.B., R.G., L.K., J.S., W.-D.H.), and Departments of Neurology (C.D., B.B., J.S., M.N., W.-D.H.) and Neurosurgery (F.S., G.B.), University of Cologne, Cologne, Germany. * To whom correspondence should be addressed. E-mail: chris{at}pet.mpin-koeln.mpg.de.
Background and Purpose--To predict malignant course in patients with large middle cerebral artery (MCA) infarction, we combined PET imaging and neuromonitoring, including microdialysis. Methods--Thirty-four patients with stroke of >50% of the MCA territory in early cerebral CT scan were included. Probes for microdialysis and measurement of intracranial pressure and tissue oxygen pressure (PtO2) were placed into the ipsilateral frontal lobe. PET was performed with 11C-flumazenil to assess CBF and irreversible neuronal damage. Results--PET measurements within 24 hours after stroke showed larger volumes of ischemic core (mean, 144.5 versus 62.2 cm3) and larger volumes of irreversible neuronal damage (157.9 versus 47.0 cm3) in patients with malignant course (ie, edema formation with midline shift) than in patients with benign course. Mean cerebral blood flow values within the ischemic core were significantly lower and the volume of the ischemic penumbra was smaller in the malignant than in the benign group. In patients with malignant course, cerebral perfusion pressure dropped to <50 to 60 mm Hg 22 to 72 hours (mean, 52.0 hours) after onset of symptoms; subsequently, PtO2 dropped and glutamate increased, indicating secondary ischemia. Maximal changes in the monitored variables reached significant levels for glutamate, aspartate, GABA, glycerol, lactate-to-pyruvate ratio, hypoxanthine, intracranial pressure, cerebral perfusion pressure, and PtO2. Conclusions--PET allowed prediction of malignant MCA infarction within the time window suggested for hemicraniectomy. Neuromonitoring helped to classify the clinical courses by characterizing pathophysiological sequelae of malignant edema formation. In contrast to PET, however, it did not predict fatal outcome early enough for successful implementation of invasive therapies.
Accepted on April 25, 2003
Prediction of Malignant Course in MCA Infarction by PET and Microdialysis
Christian Dohmen MD*;
Key words: craniectomy • excitatory amino acids • microdialysis • stroke, ischemic • tomography, emission computed
This article has been cited by other articles:
 |
|
 |
|
  J. A. Alawneh, R. R. Moustafa, and J.-C. Baron Hemodynamic Factors and Perfusion Abnormalities in Early Neurological Deterioration Stroke, June 1, 2009; 40(6): e443 - e450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jin, K. Arai, Y. Murata, S. Wang, M. F. Stins, E. H. Lo, and K. van Leyen Protecting Against Cerebrovascular Injury: Contributions of 12/15-Lipoxygenase to Edema Formation After Transient Focal Ischemia Stroke, September 1, 2008; 39(9): 2538 - 2543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takasawa, R. R. Moustafa, and J.-C. Baron Applications of Nitroimidazole In Vivo Hypoxia Imaging in Ischemic Stroke Stroke, May 1, 2008; 39(5): 1629 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ponce, N. P. de la Ossa, O. Hurtado, M. Millan, J. F. Arenillas, A. Davalos, and T. Gasull Simvastatin Reduces the Association of NMDA Receptors to Lipid Rafts: A Cholesterol-Mediated Effect in Neuroprotection Stroke, April 1, 2008; 39(4): 1269 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Dohmen, B. Bosche, R. Graf, T. Reithmeier, R.-I. Ernestus, G. Brinker, J. Sobesky, and W.-D. Heiss Identification and Clinical Impact of Impaired Cerebrovascular Autoregulation in Patients With Malignant Middle Cerebral Artery Infarction Stroke, January 1, 2007; 38(1): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bosche, G. F. Hamann, C. Dohmen, R. Graf, J. Serena, M. Castellanos, J. Castillo, M. Blanco, and A. Davalos There Is More to it Than: the Greater the Infarction Volume, the More Probable Is a Malignant MCA Infarction Stroke, March 1, 2006; 37(3): 762 - 764. [Full Text] [PDF]
|
|
|
|
|
|
J. Serena, M. Blanco, M. Castellanos, Y. Silva, J. Vivancos, M. A. Moro, R. Leira, I. Lizasoain, J. Castillo, and A. Davalos The Prediction of Malignant Cerebral Infarction by Molecular Brain Barrier Disruption Markers Stroke, September 1, 2005; 36(9): 1921 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Foerch, B. Otto, O. C. Singer, T. Neumann-Haefelin, B. Yan, J. Berkefeld, H. Steinmetz, and M. Sitzer Serum S100B Predicts a Malignant Course of Infarction in Patients With Acute Middle Cerebral Artery Occlusion Stroke, September 1, 2004; 35(9): 2160 - 2164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhardwaj, B. Bosche, C. Dohmen, and R. Graf In Vivo Regional Neurochemistry in Stroke: Clinical Applications, Limitations, and Future Directions * Cerebral Microdialysis in Stroke Patients: Potentials and Limitations of a Method with Longitudinal Information: Response Stroke, April 1, 2004; 35(4): e74 - e76. [Full Text] [PDF]
|
|
|
|
|
|
S. Warach and J.-C. Baron Neuroimaging Stroke, February 1, 2004; 35(2): 351 - 353. [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hanley and W. Hacke Critical Care and Emergency Medicine Neurology Stroke, February 1, 2004; 35(2): 365 - 366. [Full Text] [PDF]
|
|
|
|
|
|
C. Berger and S. Schwab Editorial Comment--"Malignant" or Not: Is There a Role for In Vivo Neurochemistry? Stroke, December 1, 2003; 34(12): 2914 - 2915. [Full Text] [PDF]
|
|
|
|
|
|
B. Bosche, C. Dohmen, R. Graf, M. Neveling, F. Staub, L. Kracht, J. Sobesky, F.-G. Lehnhardt, and W.-D. Heiss Extracellular Concentrations of Non-Transmitter Amino Acids in Peri-Infarct Tissue of Patients Predict Malignant Middle Cerebral Artery Infarction Stroke, December 1, 2003; 34(12): 2908 - 2913. [Abstract] [Full Text] [PDF]
|
|